Ocular therapeutix, inc. (OCUL)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Sep'13Jun'13
Revenue:
Total revenue, net

2,609

2,256

829

650

492

504

498

648

340

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total revenue

-

-

-

-

-

-

-

-

-

-

523

438

475

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Product revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

477

441

416

394

388

334

238

193

143

97

27

-

-

Collaboration revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

42

42

41

125

188

-

-

-

-

-

-

Total revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

477

441

458

436

429

459

426

505

143

97

27

-

-

Costs and operating expenses:
Cost of product revenue

819

839

806

552

128

117

115

153

80

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cost of product revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

112

105

99

92

91

80

56

30

32

20

9

-

-

Research and development

6,098

10,125

10,235

9,414

11,317

10,258

9,685

8,745

8,227

7,908

8,126

8,117

6,729

7,328

5,686

6,978

7,073

6,886

8,263

6,743

4,719

5,148

4,482

4,292

4,958

2,784

2,404

Selling and marketing

7,130

7,142

6,777

7,225

3,347

2,291

1,067

867

717

903

3,238

6,832

6,027

2,526

1,294

1,492

1,389

1,143

798

1,041

870

658

479

535

310

148

143

General and administrative

5,176

5,551

6,155

5,058

5,358

5,121

4,447

4,447

4,771

4,279

4,230

3,724

3,276

3,002

2,623

2,973

2,406

2,590

2,451

2,230

1,894

2,216

1,926

1,196

1,575

503

442

Total costs and operating expenses

19,223

23,657

23,973

22,249

20,150

17,787

15,314

14,212

13,795

13,203

15,719

18,777

16,147

12,983

9,715

11,548

10,967

-

11,603

10,094

-

-

-

-

-

-

-

Total costs and operating expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

7,539

-

6,919

6,043

6,852

3,435

2,989

Loss from operations

-16,614

-21,401

-23,144

-21,599

-19,658

-17,283

-14,816

-13,564

-13,455

-12,716

-15,196

-18,339

-15,672

-12,472

-9,238

-11,107

-10,509

-10,275

-11,174

-9,635

-7,113

-7,547

-6,776

-5,946

-6,825

-3,435

-2,989

Other income (expense):
Interest income

139

213

308

379

329

258

230

215

176

104

115

113

92

68

69

80

87

45

53

28

40

0

5

1

1

-

-

Interest income

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3

3

Interest expense

1,633

1,805

1,651

1,627

1,018

374

424

455

486

490

491

468

443

418

426

418

418

408

406

405

505

407

412

257

43

94

107

Change in fair value of derivative liability

-3,404

-3,024

5,717

-1,606

3,223

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other income (expense), net

-

-

-8

-

-

-

-

-

-

-

5

-

-

-

-1

-

-

-

3

3

-

0

-111

-190

-141

4

3

Total other income (expense), net

-4,898

-4,616

4,366

-2,854

2,534

-116

-194

-240

-310

-386

-371

-355

-351

-350

-358

-338

-331

-362

-350

-374

-465

-407

-518

-446

-183

-87

-101

Net loss and comprehensive loss

-21,512

-26,017

-18,778

-24,453

-17,124

-17,399

-15,010

-13,804

-13,765

-13,102

-15,567

-18,694

-16,023

-12,822

-9,596

-11,445

-10,840

-10,637

-11,524

-10,009

-7,578

-7,954

-7,294

-6,392

-7,008

-3,522

-3,090

Net loss per share, basic

-0.41

-

-0.40

-

-0.41

-

-0.38

-

-0.40

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Weighted average common shares outstanding, basic

51,900

-

46,944

-

42,251

-

39,017

-

34,792

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss per share, diluted

-0.41

-

-0.45

-

-0.45

-

-0.38

-

-0.40

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Weighted average common shares outstanding, diluted

51,900

-

52,713

-

44,174

-

39,017

-

34,792

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accretion of redeemable convertible preferred stock to redemption value

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

5

6

-

-

Accretion of redeemable convertible preferred stock to redemption value

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-5

-9

Net loss attributable to common stockholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-7,954

-7,294

-6,397

-7,014

-3,527

-3,099

Net loss per share, basic and diluted

-

-

-

-0.57

-

-

-

-0.37

-

-0.44

-0.54

-0.64

-0.58

-0.51

-0.39

-0.46

-0.44

-0.44

-0.47

-0.45

-0.35

2.34

-0.48

-2.10

-2.45

-1.34

-1.19

Weighted average common shares outstanding, basic and diluted

-

-

-

42,910

-

-

-

37,524

-

29,515

29,087

29,026

27,643

24,889

24,853

24,770

24,751

24,733

24,713

22,167

21,362

21,541

15,165

3,044

2,859

2,624

2,595

Comprehensive loss:
Net loss

-21,512

-26,017

-18,778

-24,453

-17,124

-17,399

-15,010

-13,804

-13,765

-13,102

-15,567

-18,694

-16,023

-12,822

-9,596

-11,445

-10,840

-10,637

-11,524

-10,009

-7,578

-7,954

-7,294

-6,392

-7,008

-3,522

-3,090

Other comprehensive loss:
Unrealized gain on marketable securities

-

-

-

-

-

-

-

-

-

0

0

9

-4

-10

-5

10

68

-

-8

-8

-

-

-

-

-

-

-

Total other comprehensive income

-

-

-

-

-

-

-

-

-

0

0

9

-4

-10

-5

10

68

-

-8

-8

-

-

-

-

-

-

-

Total comprehensive loss

-

-

-

-

-

-

-

-

-

-13,102

-15,567

-18,685

-16,027

-12,832

-9,601

-11,435

-10,772

-10,689

-11,532

-10,017

-7,578

-

-7,294

-6,392

-

-

-